Creatinine/cystatin C ratio as a surrogate marker of residual muscle mass in amyotrophic lateral sclerosis

Neurology and Clinical Neuroscience

Volumn 1, Issue 1, 2013, Pages 32-37

  Tetsuka, Syuichi ^a   Morita, Mitsuya ^a   Ikeguchi, Kunihiko ^a   Nakano, Imaharu ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Amyotrophic lateral sclerosis; Creatinine; Cystatin C; Residual muscle mass; Surrogate maker

Indexed keywords

CREATININE; CYSTATIN C;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUSCLE MASS; PRIORITY JOURNAL;

EID: 84926190886     PISSN: None     EISSN: 20494173     Source Type: Journal    
DOI: 10.1002/ncn3.11     Document Type: Article

References (23)

1. Winhammar JM, Rowe DB, Henderson RD, Kiernan MC. Assessment of disease progression in motor neuron disease. Lancet Neurol. 2005; 4: 229-38.
2. Turner MR, Kiernan MC, Leigh PN, Talbot K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol. 2009; 8: 94-109.
3. DiBernardo AB, Cudkowicz ME. Translating preclinical insights into effective human trials in ALS. Biochim. Biophys. Acta 2006; 1762: 1139-1149.
4. Bowser R, Cudkowicz M, Kaddurah-Daouk R. Biomarkers for amyotrophic lateral sclerosis. Expert Rev. Mol. Diagn. 2006; 6: 387-398.
5. Wagner KR. The need for biomarkers in amyotrophic lateral sclerosis drug development. Neurology 2009; 72: 11-12.
6. Kiernan MC, Vucic S, Cheah BC et al. Amyotrophic lateral sclerosis. Lancet 2011; 377: 942-55.
7. Lee CD, Song Y, Peltier AC, Jarquin-Valdivia AA, Donofrio PD. Muscle ultrasound quantifies the rate of reduction of muscle thickness in amyotrophic lateral sclerosis. Muscle Nerve 2010; 42: 814-9.
8. Rutkove SB, Zhang H, Schoenfeld DA et al. Electrical impedance myography to assess outcome in amyotrophic lateral sclerosis clinical trials. Clin. Neurophysiol. 2007; 118: 2413-8.
9. Hashizume A, Katsuno M, Banno H et al. Longitudinal changes of outcome measures in spinal and bulbar muscular atrophy. Brain 2012; 135: 2838-48.
10. Abrahamson M, Olafsson I, Palsdottir A et al. Structure and expression of the human cystatin C gene. Biochem. J. 1990; 268: 287-294.
11. Filler G, Bokenkamp A, Hofmann W, Le Bricon T, Martinez-Bru C, Grubb A. Cystatin C as a marker of GFR-history, indications, and future research. Clin. Biochem. 2005; 38: 1-8.
12. Newman DJ. Cystatin C. Ann. Clin. Biochem. 2002; 39: 89-104.
13. Grubb A, Löfberg H. Human gamma-trace, a basic microprotein: Amino acid sequence and presence in the adenohypophysis. Proc. Natl Acad. Sci. USA 1982; 79: 3024-7.
14. Vinge E, Lindergard B, Nilsson-Ehle P, Grubb A. Relationships among serum cystatin C, serum creatinine, lean tissue mass and glomerular filtration rate in healthy adults. Scand. J. Clin. Lab. Invest. 1999; 59: 587-592.
15. Brooks BR, Miller RG, Swash M, Munsat TL. World federation of neurology research group on motor neuron diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2000; 1: 293-299.
16. Cedarbaum JM, Stambler N, Malta E et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNFALS Study Group (Phase III). J. Neurol. Sci. 1999; 169: 13-21.
17. Tanaka M, Matsuo K, Enomoto M, Mizuno K. A sol particle homogeneous immunoassay for measuring serum cystatin C. Clin. Biochem. 2004; 37: 27-35.
18. Matsuo S, Imai E, Horio M et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am. J. Kidney Dis. 2009; 53: 982-92.
19. Rule A, Bergstralh EJ, Slezak JM, Bergert J, Larson TS. Glomerular filtration rate estimated by cystatin C among different clinical presentation. Kidney Int. 2006; 69: 399-405.
20. Miller RG, Rosenberg JA, Gelinas DF et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommitte of the American Academy of Neurology: ALS Practice Parameters Task Force. Neurology 1999; 52: 1311-1323.
21. Pradat PF, Dubourg O, de Tapia M et al. Muscle gene expression is a marker of amyotrophic lateral sclerosis severity. Neurodegener. Dis. 2012; 9: 38-52.
22. Bryan WW, Reisch JS, McDonald G, Herbelin LL, Barohn RJ, Fleckenstein JL. Magnetic resonance imaging of muscle in amyotrophic lateral sclerosis. Neurology 1998; 51: 110-3.
23. Baumgartner RN, Ross R, Heymsfield SB. Does adipose tissue influence bioelectric impedance in obese men and women. J. Appl. Physiol. 1998; 84: 257-262.